医疗ETF（159828）连续5日迎净流入，小核酸进军慢病，如箭在弦

Core Viewpoint - The medical ETF (159828) has seen a net inflow for five consecutive days, driven by the advancements in the small nucleic acid sector, particularly with Arrowhead Pharmaceuticals making significant strides in chronic disease treatment and CNS (central nervous system) breakthroughs [1]. Group 1: Company Developments - Arrowhead Pharmaceuticals' market capitalization increased by $1.66 billion last week, indicating strong investor confidence [1]. - The company's first small nucleic acid product, Plozasiran, is set to receive FDA approval on November 18, 2025, marking a pivotal moment in its commercialization journey [1]. - Arrowhead is advancing its pipeline products towards larger patient markets in chronic diseases and CNS, showcasing its growth potential [1]. Group 2: Industry Insights - The medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies in the pharmaceutical and healthcare sectors from the Shanghai and Shenzhen markets [1]. - The index primarily covers sectors such as medical devices, medical services, and medical R&D outsourcing, reflecting the overall performance of related listed companies [1]. - The constituent stocks of the index tend to be small to mid-cap, characterized by high growth potential and volatility [1].